BIONYSELaboratory Analytical InstrumentsFiscal year ends December 31Also trades as BIO.B
BIO-RAD LABORATORIES, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$352.82−0.88 (-0.25%)
Close on Oct 19, 2026
- Market cap
- $9.46B
- P/E (TTM)
- 42.8
- Dividend yield
- –
Share price
+$42.80 (+13.81%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
BIO-RAD LABORATORIES, INC. grew revenue 1.4% to $2.59B over the twelve months to Jun 30, 2026. Operating income fell 76.3% to $53.10M, moving the operating margin from 8.8% to 2.1%. Free cash flow was $353.10M, down 4.8% from a year earlier.
Revenue
$2.59B
+1.4% vs. a year earlier
Operating income
$53.10M
-76.3% vs. a year earlier
Free cash flow
$353.10M
-4.8% vs. a year earlier
EPS, diluted
$8.25
-29.7% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $9.46B
- P/E ratio
- 42.8
- Price to sales
- 3.65
- Price to book
- 1.32
- Dividend yield
- –
- Free cash flow yield
- 3.73%
Fundamentals
- Revenue
- $2.59B
- Net income
- $222.40M
- EPS, diluted
- $8.25
- Free cash flow
- $353.10M
- Book value per share
- $267.54
- Diluted shares
- 27M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$2.59B+1.4% YoY
Gross profit
$1.34B-0.4% YoY
Operating income
$53.10M-76.3% YoY
Net income
$222.40M-30.3% YoY
EPS, diluted
$8.25-29.7% YoY
Free cash flow
$353.10M-4.8% YoY
Reported periodTrailing twelve months